Institutional members access full text with Ovid®

Share this article on:

New Antiseizure Medication Approved

Aschenbrenner, Diane S. MS, RN

AJN The American Journal of Nursing: March 2014 - Volume 114 - Issue 3 - p 22
doi: 10.1097/01.NAJ.0000444487.71962.61
Drug Watch
  • Eslicarbazepine acetate (Aptiom) is a new voltage-gated sodium channel inhibitor approved for use in the treatment of partial-onset seizures. It's used as part of combination therapy.
  • The most common adverse effects are similar to those of many other antiepileptic drugs and include central nervous system and gastrointestinal effects. The drug also carries risks of serious skin reactions, drug reactions with eosinophilia and systemic symptoms, anaphylaxis, significant hyponatremia, and liver injury.

Diane S. Aschenbrenner recently retired as course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: daschen1@jhu.edu.

© 2014 Lippincott Williams & Wilkins. All rights reserved.